… in SARS-COV-2 isolates … REGEN-COV, as well as in preclinical in vitro studies using single,
dual, or triple antibody combinations, and in hamster in vivo studies using REGEN-COV or …

… effects of antiviral antibody treatment on virus evolution in humans. As predicted by our in
vitro and in vivo preclinical studies, treatment with the REGEN-COV cocktail in the clinic did not …

… This article addresses why SARS-CoV-2 is so different from … carry the human ACE2 gene for
research on SARS-CoV are … therapies and vaccines (clinical and preclinical), COVID-19 trial …

… RT-qPCR serologic testing at a central laboratory to be negative for SARS-CoV-2 at baseline;
… predicted neutralization target concentration (according to preclinical data) as early as the …

… In vitro studies showed that this antibody cocktail, REGEN-COV, retains activity against
current … the predicted neutralization target concentration based on in vitro and preclinical data. …

… In vitro studies demonstrated that REGEN-COV retains activity against current VOCs …
preclinical studies predict REGEN-COV protection against emergence of viral escape in humans…

… by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is highly variable; while
… morbidity and mortality associated with SARS-CoV-2 infection in hospitalized patients. In a …

… shown consistently in REGEN-COV clinical studies, a larger … concentration, based on in vitro
and preclinical data, 19 – 21 on … evidence from phase 3 REGEN-COV clinical studies 24 , 28 …

… The two human sequence antibodies, casirivimab and … SARS-CoV-2 serology testing
and central lab PCR testing were … concentration based on in vitro and preclinical data [10-12]. …

… of REGEN‐COV on the delta variant of SARS‐CoV‐2 is … values in patients receiving
REGEN‐COV reveals enhanced viral … REGEN‐COV antibody cocktail‐treated high‐risk …